New Drug Reverses Alzheimer's Memory Loss in Mice Using Epigenetic Approach

A New Target in the Fight Against Alzheimer's

Researchers at the University of Barcelona have designed a groundbreaking experimental compound called FLAV-27 that reversed memory loss in multiple animal models of Alzheimer's disease. Unlike existing approved treatments such as lecanemab and donanemab, which work by clearing amyloid plaques from the brain, FLAV-27 takes an entirely different approach by targeting the brain's epigenetic machinery.

How FLAV-27 Works

The drug blocks an enzyme called G9a, which plays a central role in silencing genes essential for memory formation, synaptic plasticity, and neuronal health. By preventing the natural molecule S-adenosylmethionine from accessing this enzyme, FLAV-27 slows the epigenetic dysregulation characteristic of Alzheimer's and allows neurons to regain normal function. Structural studies confirmed it achieves exceptional potency with strong selectivity and robust brain penetration.

Impressive Preclinical Results

FLAV-27 was tested across a range of models with promising results. In cell cultures, it reduced amyloid-beta and phosphorylated tau aggregation. In the worm C. elegans, it improved mobility, lifespan, and mitochondrial respiration. In two distinct mouse models representing both late-onset and early-onset Alzheimer's, the drug rescued memory performance, social behaviour, and synaptic structure.

A particularly significant translational finding was the identification of blood-based biomarkers that correlated with disease severity and normalised after treatment. These peripheral indicators could enable patient selection and treatment monitoring through a simple blood test in future clinical trials.

Road to Human Trials

The research was published in the journal Molecular Therapy. Development will now be led by Flavii Therapeutics, a University of Barcelona spin-off founded in twenty twenty-five. The company holds the exclusive licence for FLAV-27 and will manage preclinical and clinical development, with the next steps including regulatory toxicology studies and preparation of regulatory dossiers for clinical trial authorisation.